PET with the⁸⁹Zr-Labeled Transforming Growth Factor-β Antibody Fresolimumab in Tumor Models

Abstract

Fresolimumab tumor uptake and organ distribution can be visualized and quantified with (89)Zr-fresolimumab PET. This technique will be used to guide further clinical development of fresolimumab and could possibly identify patients most likely to benefit.